• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Disciplined Traders Could Go Long Aphria for a Recovery Rally

The charts of the cannabis producer indicate that its shares have found a support level.
By BRUCE KAMICH
Aug 06, 2019 | 08:19 AM EDT
Stocks quotes in this article: APHA, HAIN

For the Executive Decision segment of his "Mad Money" program Monday, Jim Cramer sat down with Irwin Simon, chairman and interim CEO at Aphria Inc. (APHA) , a Canada-based marijuana producer.

Simon said Aphria is one of the largest cannabis producers in Canada, employing over 1,100 people. Aphria currently does no business in the U.S. and is focused on the medical and recreational markets. Cannabis is big business, Simon noted, and Aphria has 550,000 plants growing in multiple facilities that employ the latest in robotic processing.

When asked why he made the jump from 25 years in the food business to cannabis, Simon said he explored the many applications of cannabis while still at Hain Celestial (HAIN) , and with so many uses from recreational to medical, food, drinks and supplements, it's clear cannabis will be a big industry.

Let's take a look at the charts and indicators to see if this is the right time to buy Aphria.

In this daily bar chart of APHA, below, we can see some big swings in the past 12 months, but let's concentrate on the lows in December and more recently. After a decline from around $16 in September, buyers came in around the $6-$4 area in December. Trading volume was very heavy as some traders probably dumped long positions and others used the dip as an opportunity to buy. Prices managed to double with a rebound to around $10, and then we saw a four-month retreat back to the $5 area.

Aphria recently gapped to the upside on heavy volume, creating what might become a double bottom pattern. Prices closed above the declining 50-day moving average line. A close above $8 and a bit will put this stock above the declining 200-day line. The On-Balance-Volume (OBV) line shows a similar double bottom (fingers crossed) and the Moving Average Convergence Divergence (MACD) oscillator is crossing to the upside for a cover shorts buy signal.

In this weekly bar chart of APHA, below, we can see that the $6-$4 area has been important resistance and now support going back to 2016. Prices are below the declining 40-week moving average line, but a weekly close above $8 will change that. The OBV line looks like it can turn up, and so does the MACD oscillator.

In this Point and Figure chart of APHA, below, we can see that a trade at $7.70 will be positive and a price target of $11 is projected.

Bottom line strategy: Experienced traders who are disciplined could consider going long APHA at current levels risking below $4. Targets are $11 and then $14.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Consumer | Marijuana | Mad Money | Executive Interview | Real Money | Cannabis

More from Stocks

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login